I AM A NUMBER DUMMY!!
A term I use for the general public MIDDLE CLASS. We are the financially uneducated, unexposed to the stock market and financial investments. Most of us don't even know what the fiscal cliff is. One woman thought it was 70 ft. tall! WOW!
I for one, think we should start teaching our kids financial responsibilities in schools, at an early age. How about a REAL education for once.
Why we need classes like home eck is beyond me. Cooking & sewing?? Read the box & microwave it! I for one support a small tax on investment income to support financial education in public schools. Could help save America.
I'm coming to the game late, so I'm quite aggressive towards growth.
My thoughts on the fiscal cliff?? Shove ur scare tactics where the sun don't shine!!
As for investing, I shoot from the hip. I go with my gut. Common sense goes along way. I don't buy hype. EPS what? What ticker is that?
HISTORY; 20 yrs. prototype machinist. 12 yrs. construction labor, management, owner.
Current; Investments & gardening (yes, profitable..gardening that is ;)
I have lived in Hong Kong since 1993 since moving here from the USA. I opened my own trading company in 2003 specializing as a master distributor of food and feed ingredients. I have been managing my own portfolio for more than 20 years and like to keep a divirsified porfolio with a goal of performing as good as the market or better over the long term.
Tobin Smith, founder/CEO of NBT Group, Inc. and Chief Research Officer NBT Equities Research LLC .Editor-In-Chief NextBigThingInvestor.com and Next Big Thing Investor Pro Newsletter. Fox News market analyst/contributor since 2000 and Fox Business Network guest anchor since 2007. NBTEquitiesEesearch.com is our sponsored research web-site. Founded ChangeWave Research LLC, one of the first expert-network primary research organizations in 1998...sold to 451 Group in 2010. NY Times bestselling investment book ChangeWave Investing 2000 and ChangeWave Investing 2.0 2002
I have been trading stocks and options for about 20 years. I own my own business and don't like watching the news anymore. Manipulation in the market is out of hand. You just have to hope your on the side of the manipulation.
I am a long and short term trader that has been involved with the stock market for many years. Primarily a technical analyst to trade, I enjoy diving into the microcap stock world looking for hidden gems. I am looking for companies that meet a select criteria of strong management, products either already on the market or possibly "in the pipeline" for biotechs. I never completely finish my due diligence when I discover a company that I like as I will maintain constant contact with a member of upper level management on a regular basis.
OTC Showcase is in the business of providing corporate information to create market and public awareness for publicly traded companies and do so through our website and affiliates. In some cases, OTC Showcase has been compensated to provide the information to the public. In some cases, the information is provided to us and we do all that we can to ensure the accuracy of the information, but cannot guarantee all information to be accurate. Information in our emails, press releases, message board postings and on our Web site may contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934 and must be realized as such. We are not licensed financial advisors in any way, shape or form and none of the information provided should be used as investment advice. Always consult a qualified and licensed financial advisor before making any investment as investing and trading can contain high elements of risk in which you may lose some or all of your money. OTC Showcase always intends to remain 100% compliant with Section 17(b) of the Security Act of 1933 and fully disclose any compensation. Please view our full disclaimer/disclosure at http://www.otcshowcase.com/?page_id=190.
Raised and currently residing in Update NY, I earned a BS at Cornell University and have worked in Energy Distribution, Home Services, and Software Design and Sales. I am an occasional investor with growing interests in pharmaceuticals and continued interest in energy.
I like analyzing stocks, especially small caps and micro caps. My firm, Carpe Diem Advisors, LLC provides investment ideas, research and analytical services. Before establishing my firm I was (for 18 years) a Managing Director of Invemed Associates LLC, a New York Stock Exchange member firm, where I performed a wide range of research and brokerage services. From 1967-1985 I was a buy side analyst and money manager (Warburg, Pincus Counselors; Manufacturers Hanover Trust Company; Arnold Bernhard & Co, where I also founded Value Line Appraisals). I have been an Adjunct Associate Professor at St. John’s University Graduate School of Business Administration and an Adjunct Assistant Professor at Touro College.
After being an active investor on and off for almost 20 years, I left my position as a senior management and information-technology consultant in 2004 and built a career trading equities and options. I began focusing on market-neutral options strategies for generating monthly income in 2006 and currently trade a portfolio comprising long-vol, short-vol, and vol-neutral options spreads. I spent four years as Chief Analyst and Trading Strategist for the Calendar Options newsletter, which was sponsored by Condor Options (www.condoroptions.com). In addition, I publish The Volatility Trader blog and am a Seeking Alpha contributor. I hold a bachelor’s degree in mathematics from the University of Pennsylvania, and currently am serving as treasurer and vice president of a small non-profit organization.
I am a small-time writer/blogger who dreams big and enjoys researching and writing about biotechs and pharmaceuticals. My work experiences include food safety, water quality, pesticides, food additives, paints, plastics and pharmaceutical precursors. My focus as of late has been researching the treatment options for many cancers and prevention of their recurrence. Additional recent research has been in the stem cell field, an exciting field in its infancy but now becoming a teenager! My ongoing goal for investors is attempting to find under-the-radar or oversold pharmaceuticals or biotechs for investment potential.